Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset)
Authors:
- 1 January 2021
- journal article
- letter
- Published by Elsevier in Thrombosis Research
- Vol. 197, 84-87
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceuticals U.S.A.
This publication has 10 references indexed in Scilit:
- Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in childrenBlood, 2020
- Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialThe Lancet Haematology, 2020
- Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studiesThe Lancet Haematology, 2019
- Potential of the Community Counts registry to characterize rare bleeding disordersHaemophilia, 2019
- Transition of care for patients with venous thromboembolism: Rationale, design and implementation of a quality intervention project conducted at American Thrombosis and Hemostasis Network (ATHN) affiliated sitesThrombosis Research, 2018
- Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and ResultsAdvances in Therapy, 2014
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- A Community-Based Partnership to Promote Information Infrastructure for Bleeding DisordersAmerican Journal of Preventive Medicine, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTEBlood, 1994